Loading...

NVBR

NBP

NOVABRIDGE BIOSCIENCES

(NBP)

2025 6-K

Executive Appointment

22 Apr '26

Business Update Report

7 Apr '26

FDA Meeting Update

16 Mar '26

Positive Study Results

9 Mar '26

Business Update Call

3 Mar '26

Investor Presentation

25 Feb '26

Board Appointment

19 Feb '26

Patient Dosing Update

17 Feb '26

Investor Presentation Update

6 Feb '26

Investor Presentation

6 Feb '26

CEO Stock Purchase

22 Jan '26

Stock Purchase Intent

22 Jan '26

Market Purchase Announcement

16 Jan '26

Positive Data Release

6 Jan '26

Financial Results Update

18 Dec '25

Positive Clinical Data

10 Dec '25

Data Presentation Announcement

4 Dec '25

Filing Update

31 Oct '25

Corporate Changes

29 Oct '25

Name Change Announcement

29 Oct '25

Acquisition Announcement

28 Oct '25

Name Change Approved

24 Oct '25

Safety Update Report

24 Oct '25

Filing Amendment Update

24 Oct '25

Research Update

23 Oct '25

I-Mab Update

22 Oct '25

Business Model Update

16 Oct '25

I-Mab Financial Update

6 Oct '25

Extraordinary Meeting Notice

24 Sep '25

Leadership Changes

8 Sep '25

Board Changes

25 Aug '25

Financial Results Update

20 Aug '25

Study Enrollment Completed

11 Aug '25

Underwritten Offering

4 Aug '25

Cash Position Report

1 Aug '25

Acquisition Announcement

17 Jul '25

ADS Offering

11 Jul '25

Filing Amendment

11 Jul '25

Positive Clinical Data

2 Jul '25

Positive Trial Results

26 Jun '25

Nasdaq Compliance

12 Jun '25

Investor Presentation

2 Jun '25

Director Appointment

30 May '25

Financial Results Update

15 May '25

Event Acceptance

30 Apr '25

Investor Presentation

4 Apr '25

Financial Results Released

3 Apr '25

Filing Notice

21 Mar '25

I-Mab Filing Update

7 Mar '25

Investor Presentation

27 Feb '25

Workforce Reduction

29 Jan '25

Investor Presentation

13 Jan '25

Board Purchases

8 Jan '25

Portfolio Prioritization

6 Jan '25

Investor Presentation

3 Dec '24

Financial Results Announced

14 Nov '24

CEO Appointment

6 Nov '24

Litigation Update

5 Nov '24

Investor Presentation

24 Oct '24

Board Resignation

23 Sep '24

Givastomig Update

16 Sep '24

Secondment Agreement

30 Aug '24

I-Mab Financial Update

28 Aug '24

Accountant Change

7 Aug '24

Filing Submission

15 Jul '24

Investor Presentation

6 Jun '24

Form 6-K Filing

5 Jun '24

Filing Announcement

23 May '24

Management Change

15 Apr '24

Divestiture Announcement

2 Apr '24

Management Changes

1 Apr '24

Financial Results Update

15 Mar '24

Strategic Asset Divestiture

7 Feb '24

Management Change

6 Feb '24

External Links:

SEC

I-Mab reported positive data from a Phase 1b trial of Givastomig combined with immunochemotherapy for first-line gastric cancer at ESMO GI 2025. This filing date is June 26, 2025, and the event is significant for investors, indicating a positive sentiment towards the company's drug development efforts.

AI Assistant

NOVABRIDGE BIOSCIENCES

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.